Drug Database · Clinicians

Meropenem

Brands (144) Merop, Meroz, Meropen…Show all
Merop · Meroz · Meropen · Amero 500 · Amsopen · Aropen · Arunem · B-PENEM IV · Carmepem · Eopenem · Ero-S · Kabimax · Mepem · Mepenem · Meromax · Meromax IV · Meronem · Meronix · Meropegen · Meropro · Meroqure-10 · Merostar · Merotam · Merozan · Merozil · Merpenem · Mirem · Mornem · Myrronem · Natronem · Plemonem 1000 · Pospenem · Romepen · Tripem · Aemero 1000 · Aemero 500 · Altacar · Amero 1G · Amero IV · Anagrapem · Anagrapem 500 · BDMERO 1000 · BDMERO 500 · Biopenem · Canem · Carbacent · Carpenem-1000 · Carpenem-500 · Dexpenem · Ecopenem-1000 · Emapen · Emero 1000 · Emero 500 · Eonem 1000 · Goprenem · Grobinem · Hyertic · Hyertic-500 · Luomepen · Maxpenem 1000 · Merilollen-BI · Meriva · Mero-X · Merobact · Merobest 1000 · Merobest 500 · Merocid · Merocy · Meroden · Merodex 1 · Merodex II · Merogen · MeroGet-500 · Merogram 1000 · Merogram 500 · Merogrand 1 · Merolev · MeroMate · Meromax 1000 · Meromax 500 · Meromed · Meronash 1000 · Meronash-500 · Meronav-1000 · Meronav-500 · Meroparm · Meroparvin · Meropdica · Meropem · Meropevex · Merophil · Meroqure-5 · Merosalus · Merosaph 1000 · Merosaph 500 · Merostan · Merotech · MEROVEX 1000 · Merovex 500 · Merowin · Meroxtar-1000 · Meroxtar-500 · Merozone · Merpetri · Merprofez 1000 · Merprofez 500 · Merrobe 1000 · Merrobe 500 · Merrovid · MERROX · Mertripen · Miro · Morep 1000 · Morfenexx 1000 · Morfenexx 500 · MPEN 1000 · Nemosea-500 · One-Mero 1000 · Oppironem · Orem-P · Pharmanem · Plemonem 500 · Prophem · Q-Penem · Retapenem · Rmero-1000 · Romapen · Ropen · Ropenefix · Shepenem-1 · Siti - Penem 1000 · Siti-Penem 500 · Sitipenam · Surinem-1000 · Surinem-500 · Symero · Syropen · Unomero 1000 · Vopenem · Welopenem · Winmero-1000 · Xanem · Zeronem · Zeronem 500

Antibacterial (carbapenem); Antibacterial (carbepenem); and others PH FDA category

Rx · Prescription drug192 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b0075b72-c3cc-f844-e053-2a95a90a417f, version date November 2, 2026 (MEROPENEM · Civica, Inc). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only).
  • Complicated intra-abdominal infections (adult and pediatric patients).
  • Bacterial meningitis (pediatric patients 3 months of age and older only).
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Meropenem for injection is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only).

(1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Complicated Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Known hypersensitivity to product components or other drugs in the same class
  • Anaphylactic reactions to beta-lactams
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Meropenem is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams. Known hypersensitivity to product components or anaphylactic reactions to β-lactams. (4)

Dosing: Adult

  • Complicated skin and skin structure infections: 500 mg IV every 8 hours (1 g every 8 hours if Pseudomonas aeruginosa)
  • Complicated intra-abdominal infections: 1 g IV every 8 hours
  • Administration: Infuse over 15 to 30 minutes; 1 g doses may also be given as an IV bolus (5 to 20 mL) over 3 to 5 minutes
  • CrCl 50 mL/min or less: 26–50: usual dose every 12 hours; 10–25: half dose every 12 hours; below 10: half dose every 24 hours
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended. (2.1)
  • 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. (2.1)
  • 1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients. (2.1)
  • Dosage should be reduced in adult patients with renal impairment. (2.2)
  • Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours Pediatric patients 3 months of age and older Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function (2.3)
  • Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Complicated skin and skin structure* 10 500 mg Every 8 hours Intra-abdominal 20 1 gram Every 8 hours Meningitis 40 2 gram Every 8 hours - Intravenous …
2.1 Adult Patients

2.1 Adult Patients The recommended dose of meropenem for injection is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P. aeruginosa, a dose of 1 gram every 8 hours is recommended.

Meropenem for injection should be administered by intravenous infusion over approximately 15 minutes to 30 minutes. Doses of 1 gram may also be administered as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.

2.2 Use in Adult Patients with Renal Impairment

2.2 Use in Adult Patients with Renal Impairment Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing Table below.) When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. Males: Creatinine Clearance (mL/min) = Weight (kg) × (140 - age) 72 × serum creatinine (mg/dL) Females: 0.85 × above value Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.

2.3 Use in Pediatric Patients

2.3 Use in Pediatric Patients Pediatric Patients 3 Months of Age and Older For pediatric patients 3 months of age and older, the meropenem for injection dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (cSSSI, cIAI, intra-abdominal infection or meningitis). See dosing Table 2 below.

For pediatric patients weighing over 50 kg administer meropenem for injection at a dose of 500 mg every 8 hours for cSSSI, 1 gram every 8 hours for cIAI and 2 grams every 8 hours for meningitis. Administer meropenem for injection as an intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.

There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose. Table 2: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Complicated skin and skin structure infections 10 500 mg Every 8 hours Complicated intra-abdominal infections 20 1 gram Every 8 hours Meningitis 40 2 grams Every 8 hours There is no experience in pediatric patients with renal impairment.

When treating cSSSI caused by P. aeruginosa, a dose of 20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended. Pediatric Patients Less Than 3 Months of Age For pediatric patients (with normal renal function) less than 3 months of age, with complicated intra-abdominal infections, the meropenem for injection dose is based on gestational age (GA) and postnatal age (PNA).

See dosing Table 3 below. Meropenem for injection should be given as intravenous infusion over 30 minutes. Table 3: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients Less than 3 Months of Age with Complicated Intra-abdominal Infections and Normal Renal Function Age Group Dose (mg/kg) Dose Interval Infants less than 32 weeks GA and PNA less than 2 weeks 20 Every 12 hours Infants less than 32 weeks GA and PNA 2 weeks and older 20 Every 8 hours Infants 32 weeks and older GA and PNA less than 2 weeks 20 Every 8 hours Infants 32 weeks and older GA and PNA 2 weeks and older 30 Every 8 hours There is no experience in pediatric patients with renal impairment.

2.4 Preparation and Administration of Meropenem for Injection Important

2.4 Preparation and Administration of Meropenem for Injection Important Administration Instructions: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intravenous Bolus Administration Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see Table 4 below).

Shake to dissolve and let stand until clear. Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials Vial Size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 500 mg 10 10 50 1 gram 20 20 50 For Infusion Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid.

Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid [see Dosage and Administration (2.5), (2.6)]. Do not use flexible container in series connections.

2.5 Compatibility

2.5 Compatibility Compatibility of meropenem for injection with other drugs has not been established. Meropenem for injection should not be mixed with or physically added to solutions containing other drugs.

2.6 Stability and Storage

2.6 Stability and Storage Freshly prepared solutions of meropenem for injection should be used. However, re-constituted solutions of meropenem for injection maintain satisfactory potency under the conditions described below. Solutions of intravenous meropenem for injection should not be frozen. Intravenous Bolus Administration Meropenem for injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of meropenem for injection) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F).

Intravenous Infusion Administration Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 15 hours at up to 5°C (41°F). Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Dextrose Injection 5% should be used immediately.

Dosing: Altered kidney function

Meropenem clearance tracks creatinine clearance (CrCl). The US label reduces the dose or extends the interval when CrCl is 50 mL/min or less; it says information is inadequate for hemodialysis or peritoneal dialysis, although meropenem is removed by hemodialysis. In critical illness, prolonged or continuous infusion of the same daily dose may be used per local protocol (label regimens are 30-minute infusions).

Kidney function measure: Label uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault).

Show full dosing details
CrCl ≥60 mL/min
Recommended dose every 8 hours (label: CrCl >50; 500 mg for complicated skin infections, 1 g for intra-abdominal infection).
CrCl 30–59 mL/min
CrCl >50: every 8 hours. CrCl 26–50: recommended dose every 12 hours (label).
CrCl 15–29 mL/min
CrCl 26–50: full dose every 12 hours. CrCl 10–25: one-half dose every 12 hours (label).
CrCl <15 mL/min (not on dialysis)
CrCl 10–25: one-half dose every 12 hours. CrCl <10: one-half dose every 24 hours (label).
Hemodialysis (intermittent)
Label: information in hemodialysis is inadequate for a dose recommendation. Meropenem is removed by hemodialysis; give any dose after the session. Current literature does not support thrice-weekly post-hemodialysis meropenem (Tsai 2025). Dose with specialist input.
Peritoneal dialysis
Inadequate information in label. For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 500 mg daily (long dwell in APD) or 1,000 mg daily (short dwell in CAPD); continuous maintenance dose 125 mg/L in each exchange (no loading dose listed). Specialist input.
CRRT
Not in label. Published CRRT regimens: 1 g every 8 hours at higher effluent rates (about 35 mL/kg/h); 1 g every 12 hours at lower effluent for susceptible organisms; consider extended infusion; adjust to residual function and MIC (Li 2020).
  • Dialyzable? Yes: readily dialyzable (label).
  • Monitoring Seizure risk higher in kidney impairment and central nervous system disease; do not combine with valproate (label class warnings).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual pediatric dosing.
eGFR 30–59
No experience in pediatric patients with renal impairment (label). Specialist input.
eGFR 15–29
No experience in pediatric patients with renal impairment (label). Specialist input.
eGFR <15 (not on dialysis)
No experience in pediatric patients with renal impairment (label). Specialist input.
Hemodialysis (intermittent)
No experience (label).
Peritoneal dialysis
No experience.
CRRT
No experience.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.2 Use in Adult Patients with Renal Impairment Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing Table below.) When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. Males: Creatinine Clearance (mL/min) = Weight (kg) × (140 - age) 72 × serum creatinine (mg/dL) Females: 0.85 × above value Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.

8.6 Patients with Renal Impairment Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less [see Dosage and Administration (2.2), Warnings and Precautions (5.8), Clinical Pharmacology (12.3)].

Patients with Renal Impairment Pharmacokinetic studies with meropenem in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less) [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Meropenem is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [see Overdosage (10)].

Dosing: Pediatric

Approved ages
All ages for complicated intra-abdominal infections; 3 months and older for complicated skin infections and bacterial meningitis (vial label 8.4).
Usual dose
Complicated skin infections 10 mg/kg (max 500 mg) every 8 hours (20 mg/kg if Pseudomonas aeruginosa); intra-abdominal infections 20 mg/kg (max 1 g) every 8 hours; meningitis 40 mg/kg (max 2 g) every 8 hours. Over 50 kg: adult doses (label).
Maximum dose
2 g every 8 hours (meningitis) (label).
Neonates
Under 3 months, complicated intra-abdominal infection, normal kidney function (label 2.3): GA under 32 weeks and PNA under 2 weeks, 20 mg/kg every 12 hours; GA under 32 weeks and PNA 2 weeks or older, 20 mg/kg every 8 hours; GA 32 weeks or older and PNA under 2 weeks, 20 mg/kg every 8 hours; GA 32 weeks or older and PNA 2 weeks or older, 30 mg/kg every 8 hours. Infuse over 30 minutes. No experience with kidney impairment.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of meropenem have been established for pediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for pediatric patients of all ages with complicated intra-abdominal infections. Skin and Skin Structure Infections Use of meropenem in pediatric patients 3 months of age and older with complicated skin and skin structure infections is supported by evidence from an adequate and well-controlled study in adults and additional data from pediatric pharmacokinetics studies [see Indications and Usage (1.3), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)].

Intra-abdominal Infections Use of meropenem in pediatric patients 3 months of age and older with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetics studies and controlled clinical trials in pediatric patients. Use of meropenem in pediatric patients less than 3 months of age with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from a pediatric pharmacokinetic and safety study [see Indications and Usage (1.2), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.2)].

Bacterial Meningitis Use of meropenem in pediatric patients 3 months of age and older with bacterial meningitis is supported by evidence from adequate and well-controlled studies in the pediatric population [see Indications and Usage (1.3), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.3)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects in clinical studies of meropenem, approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure infections, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older.

No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. A pharmacokinetic study with meropenem in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance [see Clinical Pharmacology (12.3)].

Administration

2.4 Preparation and Administration of Meropenem for Injection Important Administration Instructions: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intravenous Bolus Administration Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see Table 4 below). Shake to dissolve and let stand until clear. Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials Vial Size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 500 mg 10 10 50 1 gram 20 20 50 For Infusion Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid. Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid [ see Dosage and Administration (2.5) , (2.6) ] . Do not use flexible container in series connections.

2.5 Compatibility Compatibility of meropenem for injection with other drugs has not been established. Meropenem for injection should not be mixed with or physically added to solutions containing other drugs.

US FDA label

Dosage forms

Philippines

  • Powder for injection: 1 g, 500 mg, 500 mg 500 mg
  • Powder for solution for injection: 1 g, 500 mg
  • Powder for iv injection: 1 g, 500 mg
  • Powder for i.v. injection: 500 mg
  • Powder for intravenous injection: 1 g
  • Powder for solution for i.v. injection: 500 mg
  • Powder for solution for intravenous injection: 500 mg
  • Powder for solution for iv injection/infusion: 1 g
  • Powder fr injection iv: 1 g
  • Sterile powder for injection: 1 g

Registered products in the Philippines

192 products registered with the Food and Drug Administration (FDA) Philippines list Meropenem as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products192
Philippine FDA-registered products for Meropenem
Package insert
Aemero 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and sealed with aluminum flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DR-XY49036
Apr 5, 2029
Aemero 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and sealed with aluminum flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DR-XY49037
Apr 5, 2029
AltacarMeropenem (as trihydrate)
1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20mL (5 Vials per Plastic Tray) (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Justright Healthcare Inc.Importer: JLT Pharma Inc.
DRP-6955-06
Jan 4, 2027
Amero 1GMeropenem (As Trihydrate)
1 g Powder For Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of l's)
Rx
Brooks Laboratories LimitedIndia
Biocare Lifesciences, Inc.
DRP-11441
Mar 14, 2027
Amero 500Meropenem (as trihydrate)
500 mg Powder for Injection (IV)Type I Transparent Flint Glass Vial x 20 mL (Box of 1's)
Rx
ZEISS PHARMACEUTICALS PVT. LTD.India
BIOCARE LIFESCIENCES, INC.Importer: Glenmark Philippines, Inc.Trader: GLENMARK PHARMACEUTICALS LTD.
DRP-7690-02
Feb 6, 2028
Amero 500Meropenem (As Trihydrate)
500mg Powder For Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Laboratories LimitedIndia
Biocare Lifesciences, Inc.
DRP-11442
Mar 14, 2027
Amero IVMeropenem (as trihydrate)
1 g Powder for Injection (IV)Type I Transparent Flint Glass Vial x 20 mL Box of 1's
Rx
ZEISS PHARMACEUTICALS PVT. LTD.India
BIOCARE LIFESCIENCES, INC.Importer: Glenmark Philippines, Inc.Trader: GLENMARK PHARMACEUTICALS LTD.
DRP-7691-01
Feb 7, 2028
AmsopenMeropenem (as trihydrate)
1 g powder for injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC
Rx
Aristopharma Ltd.Bangladesh
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.
DRP-10152-01
Sep 5, 2028
AmsopenMeropenem (as trihydrate)
500 mg Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC
Rx
Aristopharma Ltd.Bangladesh
Amson PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-10150-01
Sep 5, 2028
AnagrapemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1's
Rx
Mepromax Lifesciences Pvt. Ltd.India
Nordlich Pharma, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557-04
Dec 15, 2029
Anagrapem 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1’s)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Nordlich Pharma, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-12129-04
Dec 15, 2029
AropenMeropenem (as trihydrate)
1 g Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule x 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC
Rx
Aristopharma Ltd.Bangladesh
SAHAR INTERNATIONAL TRADING, INC.
DRP-10152
Sep 5, 2028
AropenMeropenem (as trihydrate)
500 mg Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading, Inc.
DRP-10150
Sep 5, 2028
ArunemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557-05
Dec 15, 2029
ArunemMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-12129-03
Dec 15, 2029
B-PENEM IVMeropenem (As Trihydrate)
1 g Powder For Injection ( IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Laboratories LimitedIndia
Biocare Lifesciences, Inc.
DRP-11443
Mar 14, 2027
B-PENEM IVMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of l's)
Rx
Brooks Laboratories LimitedIndia
Biocare Lifesciences, Inc.
DRP-12574
Sep 14, 2027
BDMERO 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1's
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557
Dec 15, 2029
BDMERO 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-12129
Dec 15, 2029
BiopenemMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-07
Mar 6, 2027
CanemMeropenem (As Trihydrate)
1 g Powder for Injection (IV)20 mL USP Type I Flint Glass Vial (Box of 1's)
Rx
Shamshree Lifesciences Ltd.India
Britton Distributions Inc.Importer: Genpharm, Inc.Trader: Cachet Pharmaceuticals Pvt., Ltd.
DR-XY38582
Jan 27, 2030
CarbacentMeropenem
1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1 's)
Rx
Uni MedicolabsIndia
Central West Medicale Inc.Importer: Greencore Pharma Inc.
DRP-11927-04
May 20, 2027
CarmepemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30 mL (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc.
DRP-6955-03
Jan 4, 2032
CarmepemMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc.
DRP-7859-03
May 31, 2028
Carpenem-1000Meropenem (as Trihydrate)
1 g Powder For Injection (I.V.)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip- Off Seal Cap x 1's+ 10 mL Sterile Water for Injection in Type I Clear Colorless Glass Ampoule (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Importer: FSPC Pharmaceuticals, Inc.
DRP-13129
Dec 5, 2027
Carpenem-500Meropenem (as Trihydrate)
500 mg Powder For Injection (I.V.)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip- Off Seal Cap x 1's + 10 mL Sterile Water for Injection in Type I Clear Colorless Glass Ampoule (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals, Inc.
DRP-13128
Dec 5, 2027
DexpenemMeropenem (as trihydrate)
1 g Powder for Injection1 g in a Type I, Clear, colorless glass vial (Box of 1's)
Rx
PT DEXA MEDICAIndonesia
Glorious Dexa Mandaya, Inc
DRP-8460
Apr 16, 2029
Ecopenem-1000Meropenem
1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1 's)
Rx
Uni Medicolabs Inc.India
Planetarium Enterprise, Inc.Importer: Greencore Pharma, Inc.
DRP-11927-03
May 20, 2027
EmapenMeropenem (as trihydrate)
1 g Powder for Solution for Injection (I.V.)USP Type II Glass Vial (Box of 1 vial)
Rx
Maxitech Pharma (Pvt) Ltd.Pakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-15004
Mar 7, 2029
Emero 1000Meropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL-capacity Type I clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Ellebasy Medicale Group Inc.Importer: One Dexcel Pharma Inc.
DRP-12537-02
Aug 31, 2027
Emero 500Meropenem (as trihydrate)
500 mg Powder for Injection (IV)Type I Clear Glass Vial x 20 mL with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Ellebasy Medicale Group Inc.Importer: One Dexcel Pharma Inc.
DRP-12540-02
Aug 30, 2027
Eonem 1000Meropenem (as trihydrate)
1 g Powder For Injection (I.V.)20 mL Type I clear glass vial 10 mL ampoule Sterile Water for Injection (as diluent) [Box of 1's]
Rx
Brwan Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-14001
Jun 1, 2028
EopenemMeropenem
1 g Powder For Injection (IV)Type II Clear Glass Vial with Gray Rubber Stopper and Green Aluminum Flip-Top Cap xl's (Box l's)
Rx
Zee Laboratories LimitedIndia
Importer: Eon Pharmatek, Inc.
DR-XY47718
Feb 10, 2027
EopenemMeropenem
1 g Powder for Injection (IV)Type II Clear Glass Vial with Gray Rubber Stopper and Green Aluminum Flip-Top Cap x 1's (Box 1's)
Rx
—
Eon Pharmatek Inc.
DRP-15051
Feb 10, 2027
Ero-SMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Starpharm, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-04
Mar 6, 2027
ERO-SMeropenem
500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1 's)
Rx
Uni MedicolabsIndia
Starpharm, Inc.Importer: Greencore Pharma Inc.
DRP-11926-02
May 20, 2027
GoprenemMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type I clear and colorless glass vial (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Applied Pharmaceutical Distribution IncImporter: JLT Pharma Inc.
DRP-7859-02
May 31, 2028
GrobinemMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Medarruz Pharmaceutical Philippines Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-10
Mar 6, 2027
HyerticMeropenem (as trihydrate)
1 g Powder for Intravenous (I.V.) InjectionUSP Type I Glass Vial x 20 mL (Box of l's)
Rx
Brooks Steriscience LimitedIndia
Orange Biotec Inc.
DRP-12721
Sep 28, 2027
Hyertic-500Meropenem (as trihydrate)
500 mg Powder for Solution for Injection (IV)20 mL-capacity USP Type I Clear Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Orange Biotec Inc.
DRP-13605
Mar 16, 2028
KabimaxMeropenem (as trihydrate)
1 g Powder for Solution for Injection (IV)Type III glass vial x 20 mL with rubber stopper and aluminum grey flip-off cap Box of 10's
Rx
ACS DOBFAR S.P.AItaly
Importer: Fresenius Kabi Philippines, Inc.
DR-XY46786
Dec 20, 2029
KabimaxMeropenem (as trihydrate)
500 mg Powder for Solution for Injection (IV)Type III glass vial x 20mL with rubber stopper and aluminum purple flip-off cap (Box of 10's)
Rx
ACS DOBFAR S.P.A.Italy
Importer: Fresenius Kabi Philippines, Inc.
DR-XY46787
Dec 20, 2029
LuomepenMeropenem (as trihydrate)
500 mg 500 mg Powder for Injection (I.M./I.V.)10 mL molded soda-lime glass vial with halogenated butyl rubber stopper and sky-blue aluminum-plastic combination cap (Box of 1's)
Rx
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China
Luoxin Pharmaceuticals (PH) Corp.
DR-XY49360
Mar 21, 2030
Maxpenem 1000Meropenem
1g Powder for Injection (I.V.)20 mL USP Type I Clear Moulded Glass Vial Sealed with Butyl Rubber Stopper and Blue Aluminum Plastic Cap (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-17074
Sep 24, 2030
MepemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30 mL (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc.
DRP-6955
Jan 4, 2032
MepemMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc.
DRP-7859
May 31, 2028
MepenemMeropenem (As Trihydrate)
1 g Powder For Injection (IV)USP Type I Colorless Glass Vial with Aluminum Seal and Violet Flip-off Cap + LDPE Vial x 10 mL as Diluent (Box of 1 Vial + 2 Diluent)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
Importer: A. Menarini Philippines, Inc.
DR-XY37067
Mar 2, 2027
MepenemMeropenem (As Trihydrate)
500 mg Powder For Injection (IV)USP Type I Colorless Glass Vial with Aluminum Seal and Purple Flip-off Cap + LDPE Vial x 10 mL as Diluent (Box of 1 Vial + Diluent)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
Trader: Phil. Pharmawealth, Inc.
DR-XY37068
Mar 2, 2027
Merilollen-BIMeropenem (as trihydrate)
1g Powder for Solution for Injection (IV)Clear glass vial with gray bromobutyl rubber stopper and aluminum seal (Box of 1's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-17395
Dec 10, 2031
MerivaMeropenem (as trihydrate)
1 g Powder for Injection (IV)Individually boxed 30 mL-capacity USP Type I clear and colorless glass vial sealed with grey bromobutyl rubber stopper and violet flip-off seal (Box of 10's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited
DRP-2151
Apr 30, 2027
Mero-XMeropenem (as Trihydrate)
1 g Powder For Solution for Injection (IV)Type I clear glass vial x 30 mL with rubber stopper and violet plastic flip-off seal (Box of 1's)
Rx
RF Life Science Private LimitedIndia
Exa Life Care Pharma Inc.
DRP-18131
May 11, 2031
MerobactMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type I clear glass vial with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap + clear glass ampoule x 5 mL Sterile Water for Injection diluent in a plastic tray (Box of 1 finished product + 1 diluent)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17552
Jan 26, 2032
Merobest 1000Meropenem
1 g Powder for Injection (I.V.)30 mL-Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
Rx
Mason PharmaIndia
Finstad Inc.
DRP-13733
Apr 3, 2028
Merobest 500Meropenem
500 mg Powder for Injection (I.V.)30 mL USP Type I tubular glass vial with 20 mm grey bromo butyl rubber stopper and 20 mm aluminum flip off-seal (Box of 1's)
Rx
Mason PharmaIndia
Finstad Inc
DRP-14683
Nov 22, 2028
MerocidMeropenem
1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Uni MedicolabsIndia
Euro-Med Laboratories Phil., Inc.Importer: Greencore Pharma Inc.
DRP-11927-08
May 20, 2027
MerocyMeropenem (as trihydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
Cyden Medical Trading Inc.Importer: AMB HK Enterprises Inc.
DRP-9055-04
Jul 16, 2031
MerodenMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Cyden Medicale Trading Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-15
Mar 6, 2027
Merodex 1Meropenem (As Trihydrate)
1 g Sterile Powder For Injection30 mL USP Type 1 glass vial with grey butyl rubber stopper and sealed with 20 mm Bio-violet color flip-off aluminum seal (Box of 1's)
Rx
KARNATAKA ANTIBIOTICS & PHARMA LTD.India
JACKSON PHARMACEUTICALS INC.Trader: VIDA LABORATORIES PVT. LTD.
DR-XY46452
Nov 14, 2028
Merodex IIMeropenem (as trihydrate)
1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20 mL (5 Vials per Plastic Tray) Box of 10's
Rx
BCWorld Healthcare Co., Ltd.Korea
Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc.
DRP-6955-04
Jan 4, 2027
MerogenMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Genzen Pharmaceutical TradingImporter: Sanimed Pharmaceuticals Inc.
DRP-7074-11
Mar 6, 2027
MeroGet-500Meropenem
500 mg Powder For Solution for Injection (IM/IV)10 mL-capacity type I clear glass vial with rubber stopper and pink aluminum flip-off seal (Box of 1's)
Rx
Venus Remedies LimitedIndia
Getmeds Philippines Inc.
DRP-18118
May 6, 2031
Merogram 1000Meropenem (as trihydrate)
1 g Powder for IV InjectionUSP Type I Clear Glass Vial (Box of 1's)
Rx
Eugia Pharma Specialities Limited-Unit 2India
Medethix, Inc.Trader: Aurobindo Pharma Limited
DR-XY45730
Jan 9, 2027
Merogram 500Meropenem
500 mg Powder for (IV) Injection15 mL Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's)
Rx
Eugia Pharma Specialities Limited Unit 2India
Medethix, Inc.Trader: Aurobindo Pharma Ltd.
DR-XY45788
Feb 23, 2027
Merogrand 1Meropenem (as trihydrate)
1g Powder for Injection (IV)20 mL Type I clear glass vial + 10 mL ampoule Sterile Water for Injection (as diluent) (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Grandis Pharma IncorporatedImporter: Sbrg Exim Philippines Inc.
DRP-14001-02
Jun 1, 2028
MerolevMeropenem
1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's)
Rx
Uni Medicolabs Inc.India
HLM Pharmaceutical Inc.Importer: Greencore Pharma Inc.
DRP-11927-02
May 20, 2027
MeroMateMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
One Technodrug Life Sciences Inc.Importer: Sanimed Pharmaceuticals Inc
DRP-7074-14
Mar 6, 2027
MeromaxMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)30 mL Type 1 Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's)
Rx
Qilu Antibiotics Pharmaceutical Co. Ltd.China
The Cathay Drug Co., Inc.
DR-XY49168
Aug 14, 2029
MeromaxMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)20 mL Type I Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's)
Rx
Qilu Antibiotics Pharmaceutical Co. Ltd.China
The Cathay Drug Co., Inc.
DR-XY49167
Aug 14, 2029
Meromax 1000Meropenem (as trihydrate)
1 g Powder for InjectionType I clear and colorless glass vial with gray butyl rubber stopper and aluminum flip-off cap (Box of 1's)
Rx
Biolab Co., Ltd.Thailand
The Cathay Drug Co., Inc.
DR-XY43150
Jan 13, 2031
Meromax 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)Type I clear and colorless glass vial with gray butyl rubber stopper and aluminum flip-off cap (Box of 1's) (Box of 1's)
Rx
Biolab Co., Ltd.Thailand
The Cathay Drug Co., Inc.
DR-XY43169
Jan 13, 2031
Meromax IVMeropenem (as trihydrate)
1 g Powder for IV InjectionType I Clear Glass Vial (Box of 1's)
Rx
Shenzhen Haibin Pharmaceutical Co., Ltd.China
The Cathay Drug Co., Inc.
DR-XY41588
Jan 24, 2031
Meromax IVMeropenem (as trihydrate)
500 mg Powder for IV InjectionType I Clear Glass Vial (Box of 1's)
Rx
Shenzhen Haibin Pharmaceutical Co., Ltd.China
The Cathay Drug Co., Inc.
DR-XY41589
Jan 26, 2031
MeromedMeropenem (As Trihydrate)
1g Powder fr Injection IVUSP TYPUSP Type 1 Glass Vial (Box of 1's)
Rx
Maan Pharmaceuticals Ltd.India
Detoxicare Philippines, Inc.Importer: Stangen Pharmaceuticals Pvt. Ltd.
DRP 6439
Nov 11, 2030
Meronash 1000Meropenem (as trihydrate)
1g Powder For Injection (Iv)20 mL USP Type I clear glass vial with grey bromobutyl rubber plug and dark green color flip-off aluminum seal (Box of 1's)
Rx
Shamshree Lifesciences Ltd.India
Khriz Pharma Trading Inc.
DR-XY48836
Aug 3, 2028
Meronash-500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)10 mL USP Type I clear glass vial with grey bromobutyl rubber plug and Turkish-blue color flip-off aluminum seal (Box of 1's)
Rx
Shamshree Lifesciences Ltd.India
Khriz Pharma Trading Inc.
DR-XY49320
Jan 27, 2030
Meronav-1000Meropenem (as Trihydrate)
1 g Powder for Injection (I.V.)30 mL USP Type I Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Red Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: AGlobal Care Inc.
DRP-12729-01
Mar 22, 2027
Meronav-500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc.
DRP-12728-01
Feb 19, 2031
MeronemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)In 30 mL type I clear glass vial Box of 1's
Rx
ACS Dobfar S.P.A.Italy
Zuellig Pharma CorporationTrader: Sumitomo Dainippon Pharma Co., Ltd.
DR-XY23416
Feb 10, 2031
MeronemMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)In 20 mL type I clear glass vial (Box of 1's)
Rx
ACS Dobfar S.P.A.Italy
Zuellig Pharma CorporationTrader: Sumitomo Dainippon Pharma Co., Ltd.
DR-XY23414
Feb 10, 2031
MeronixMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and pink flip-off seal in a plastic tray (Box of 1's)
Rx
GMH OrganicsIndia
Sanimed Pharmaceuticals Inc.
DRP-7283
Aug 3, 2027
MeronixMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and grey flip-off seal (Box of 1's)
Rx
GMH OrganicsIndia
Sanimed Pharmaceuticals Inc.
DRP-7284
Aug 3, 2027
MeropMeropenem
1 g Powder For Injection (IV)20 mL USP Type I Clear Glass Vial with Grey Rubber Stopper and Violet Flip-Off Seal (Box of 1's)
Rx
PT. Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DRP-11480
Mar 16, 2027
MeropMeropenem (as trihydrate)
1 g Powder for Injection (IV)Individually boxed 30 mL-capacity USP Type I clear and colorless glass vial sealed with grey bromobutyl rubber stopper and violet flip-off seal (Box of 10's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
UNILAB, Inc.Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited
DRP-2151-01
Apr 30, 2027
MeropMeropenem (as Trihydrate)
500 mg Powder for Injection (IV)USP Type I Clear Colorless Vial (Box of 10's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
UNILAB, Inc.Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited
DR-XY40525
Jan 13, 2027
MeropMeropenem
500 mg Powder For Injection (IV)20 mL USP Type I Clear Glass Vial with Grey Rubber Stopper and Violet Flip-Off Seal (Box of 1's)
Rx
PT. Darya-Varia Laboratoria TbkIndonesia
UNILAB, Inc.
DRP-11479
Mar 16, 2027
MeroparmMeropenem (as trihydrate)
1 g Powder for Solution for IV Injection/InfusionType III Colorless Glass Vial Sealed with Grey Rubber Stopper and Aluminum Cap x 20 mL (Box of 10's)
Rx
Anfarm Hellas S.AGreece
Aglobal Care, Inc.Trader: Veiovis Lifescience Pvt. Ltd.
DRP-15792
Sep 18, 2029
MeroparvinMeropenem
1 g Powder for Injection30 mL- Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
Rx
Mason PharmaIndia
MDB Pharma TradingImporter: Finstad Inc.
DRP-13733-01
Apr 3, 2028
MeropdicaMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type I Clear and Tubular Glass Vial with Grey Bromo Butyl Rubber Stopper and Sky Blue Plain Flip-off Aluminum Seal x 30 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Rifemedica CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557-03
Dec 15, 2029
MeropegenMeropenem (as trihydrate)
1 g Powder for Injection (IV)30mL-Type I Colorless Glass Vial Sealed with Halogenated Butyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's and 10's)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Philgen Pharmaceuticals, Inc.
DRP-16270
Jan 17, 2030
MeropegenMeropenem (as trihydrate)
500mg Powder for Injection (IV)20mL-Type I Colorless Glass Vial Sealed with gray Halogenated Buty 1 Rubber Stopper and Green Aluminum Plastic Cap x 1's (Box of 1's and 10's)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Philgen Pharmaceuticals, Inc.
DRP-16271
Jan 17, 2030
MeropemMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Ampoule Sterile Water for Injection x 10 mL (diluent) (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-10484-01
Sep 29, 2029
MeropenMeropenem (as trihydrate)
1g Powder for Injection (IV)USP Type I clear colorless glass vial, grey bromobutyl rubber stopper and yellow flip-off seal (drug product) + 10 mL Sterile Water for Injection (diluent) (Box of 1 vial drug product + 2 diluent)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DRP-1377
Jul 1, 2028
MeropenMeropenem (as trihydrate)
1g Powder for Injection (IV)20mL Type I clear glass vial + 10mL ampoule sterile water for injection (as diluent) (Box of 1’s)
Rx
Brawn Laboratories LimitedIndia
Endure Medical, Inc.Importer: Sbrg Exim Philippines Inc.
DRP-14001-01
Jun 1, 2028
MeropenMeropenem (as Trihydrate)
500 mg Powder for Injection (IV)Type I Colorless Glass Vial + 10 mL Sterile Water for Injection (as Diluent) (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY37404
Jan 25, 2030
MeropevexMeropenem (as trihydrate)
1g Powder for Injection (IV)12 ml-capacity USP Type 1 molded glass vial in individual box (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Sannovex Pharmaceutical Distributor
DR-XY44217
Feb 18, 2030
MerophilMeropenem (as trihydrate)
1 g Powder for Injection (IM/IV)20 mL-Capacity Moulded Soda Lime Glass Vial (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-9055-01
Jul 20, 2031
MeroproMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 30 mL (5 Vials per Plastic Tray) (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: JLT Pharma Inc.
DRP-6955-02
Jan 4, 2032
MeroproMeropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: JLT Pharma Inc.
DRP-7859-01
May 31, 2028
Meroqure-10Meropenem (as Trihydrate)
1 g Powder for Injection (I.V.)30 mL USP Type I clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and red flip-off seal (Box of 1's)
Rx
Ameda Pharma Pvt. Ltd.India
Aglobal Care, Inc.
DR-XY45823
Mar 22, 2027
MEROQURE-10Meropenem (As Trihydrate)
1 G POWDER FOR INJECTION (I.V.)30 Ml Usp Type I Clear And Colorless Glass Vial Sealed With 20 mm Grey Bromobutyl Rubber Stopper And Red Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals LimitedIndia
Aglobal Care, Inc.
DRP-12729
Mar 22, 2032
Meroqure-5Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial ( (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Aglobal Care, Inc.
DRP-12728
Feb 19, 2031
MerosalusMeropenem
1 g Powder for Injection (I.V.)30 mL - Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
Rx
Mason PharmaIndia
Salusa Medical Supplies And Pharmaceuticals IncImporter: Finstad Inc.
DRP-13733-02
Apr 3, 2028
Merosaph 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences Inc.
DRP-12071
Jun 7, 2027
Merosaph 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal X (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences Inc.
DRP-12072
Jun 7, 2027
MerostanMeropenem
1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1 's)
Rx
Uni MedicolabsIndia
Altor Pharmaceutical Product DistributionImporter: Greencore Pharma Inc.
DRP-11927-07
May 20, 2027
MerostarMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal (Box of 1’s)
Rx
Kilitch Drugs (India) Ltd.India
Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc.
DRP-12071-02
Jun 7, 2027
MerostarMeropenem (as Trihydrate)
1g Powder for Injection (I.V.)30mL capacity USP Type III clear and colorless glass vial (Box of 1 of vial)
Rx
Celogen Pharma Pvt. Ltd.India
Pharmastar Int'l Trading Corp.
DRP-6746
Jul 5, 2031
MerotamMeropenem
1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Uni Medicolabs, Inc.India
Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma Inc.
DRP-11927-06
May 20, 2027
MerotamMeropenem
500 mg Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's)
Rx
Uni MedicolabsIndia
Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma Inc.
DRP-11926-03
May 20, 2027
MerotechMeropenem (as trihydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1’s)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
SNV Biotech Medicinal Products WholesalingImporter: AMB HK Enterprises Inc.
DRP-9055-05
Aug 6, 2031
MEROVEX 1000Meropenem (as Trihydrate)
1 g Powder for Injection (I.V.)Tyoe I Clear glass vial with 20mm grey butyl rubber plug, crimpled aluminum with Black flip off seal (Box of 1's)
Rx
VENUS REMEDIES LIMITEDIndia
VE PHARMA INC.Trader: VEXXA LIFESCIENCES PVT. LTD.
DR-XY46387
Jun 26, 2028
Merovex 500Meropenem (as Trihydrate)
500 mg Powder for Injection (IV)Type I Clear Glass Vial with 20 mm Grey Butyl Rubber Plug, Crimped Aluminum with Black Flip-off Seal (Box rimp of 1's)
Rx
Venus Remedies Limited.India
VE Pharma, Inc.Trader: Vexxalife Sciences Pvt. Ltd.
DR-XY46386
Jun 26, 2028
MerowinMeropenem
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmceuticals Ltd.India
Tazio Lifescience Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-02
Mar 6, 2027
Meroxtar-1000Meropenem (as trihydrate)
1 g Powder for injection (I.V.)USP Type I Colorless Glass vial with Gray Bromo Butyl Rubber Stopper and Aluminum seal x 1's (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Pharmastar Int'l Trading Corp.Importer: Nelpa Lifesciences, Inc.
DRP-12071-01
Jun 7, 2027
Meroxtar-500Meropenem (as trihydrate)
500 mg Powder for injection (I.V)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal x 1's (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Pharmastar Int'l Trading Corp.Importer: Nelpa Lifesciences, Inc.
DRP-12072-01
Jun 7, 2027
MerozMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)20 mL transparent vial with gray rubber cap and deep blue flip-off cap (Box of 1's)
Rx
Dongkwang Pharm. Co., Ltd.Republic of Korea
H & B Pharma International Inc.
DRP-16944
Aug 31, 2028
MerozMeropenem (as trihydrate)
1g Powder for Injection (I.V.)20 mL USP Type I clear and colorless vial with rubber cap and flip-off cap (Box of 1's)
Rx
Dongkwang Pharm. Co., LtdKorea
PharmAsia-Cuvest Incorporated.
DR-XY48863
Aug 31, 2028
MerozMeropenem
500 mg Powder for Injection (I.V.)15 mL USP Type I Clear Glass Vial with Rubber Cap and Dark Green Flip-Off Cap (Box of 1's)
Rx
Dongkwang Pharm. Co., Ltd.Republic of Korea
H & B Pharma International Inc.
DRP-17056
Mar 16, 2027
MerozMeropenem
500 mg Powder for injection (IV)15 mL USP Type I Clear Glass Vial with Rubber Cap and Dark Green Flip-Off Cap (Box of 1's)
Rx
Dongkwang Pharma. Co., Ltd.Korea
Pharm Asia-Cuvest, Incorporated
DR-XY47826
Mar 16, 2027
MerozanMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)Type III clear and colorless glass vial in individual box NA
Rx
Demo SA Pharmaceutical IndustryGreece
Pharmasia-Cuvest Incorporated
DR-XY39209
Sep 8, 2030
MerozanMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)Type III clear and colorless glass vial in individual box
Rx
Demo SA Pharmaceutical IndustryGreece
Pharmasia-Cuvest Incorporated
DR-XY39208
Sep 8, 2030
MerozilMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type II Clear Glass Vial Box of 1's
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Global Pharmatrade
DR-XY43651
Aug 20, 2029
MerozilMeropenem (as Trihydrate)
500 mg Powder for Injection (IV)Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Global Pharmatrade
DR-XY43663
Aug 22, 2029
MerozoneMeropenem (as trihydrate)
1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30mL (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Marketzone, Inc.Importer: JLT Pharma Inc.
DRP-6955-07
Jan 4, 2027
MerpenemMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)20 mL USP Type I tubular clear glass vial with 20mm. grey butyl rubber stopper and 20 mm purple.
Rx
Venus Remedies, LimitedIndia
Triple Tact Import & Export Corp.
DRP-14909
Feb 7, 2029
MerpenemMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)10 mL USP Type I tubular clear glass vial with 20mm grey butyl rubber stopper and 20 mm pink. color flip- off aluminum seal (Box of 1's)
Rx
Venus Remedies, LimitedIndia
Triple Tact Import & Export Corp.
DRP-14910
Feb 7, 2029
MerpetriMeropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-6369-04
Oct 2, 2030
Merprofez 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1’s
Rx
Mepromax Lifesciences Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557-2
Dec 15, 2029
Merprofez 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-12129-01
Dec 15, 2029
Merrobe 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)20 mL USP Type I Transparent Flint Glass Vial (Box of 1’s)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals, Ltd.
DRP-7691
Feb 7, 2028
Merrobe 500Meropenem
500 mg Powder for Injection (I.V.)20 mL USP Type I Transparent Flint Glass Vial (Box of 1’s)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals, Ltd.
DRP-7690
Feb 7, 2028
MerrovidMeropenem (as Trihydrate)
1 g Powder For Solution For Injection (IV)20 mL-capacity USP Type I Clear Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Hovid Inc.
DRP-13349
Feb 2, 2028
MERROXMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Sanimed Pharmaceuticals Inc.
DRP-7074
Mar 6, 2027
MertripenMeropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6369-02
Apr 5, 2031
MiremMeropenem
1 g Powder for Injection (IV)30 mL-capacity type I clear glass vial with rubber stopper and alu-plastic cap (Box of 1's and 10's)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-15565
Aug 14, 2029
MiremMeropenem
500 mg Powder for Injection (IV)20 mL-capacity type I clear glass vial with rubber stopper and alu-plastic cap (Box of 1's and 10's)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-15564
Aug 14, 2029
MiroMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Sterile Water for Injection in ampoule x 10 mL (diluent) (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Pro Medica Inc.Importer: Ambica International Corporation
DRP-10484-02
Sep 29, 2029
Morep 1000Meropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Despina Pharma Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-06
Mar 6, 2027
Morfenexx 1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass Vial with Grey Bromo Butyl Rubber Stopper and Sky Blue Plain Flip-Off Aluminum Seal X 30 mL (Box of 1’s)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-10557-01
Dec 15, 2029
Morfenexx 500Meropenem (as trihydrate)
500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's)
Rx
Mepromax Lifesciences Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd.
DRP-12129-02
Dec 15, 2029
MornemMeropenem
1 g Powder For Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1’s)
Rx
Uni Medicolabs, Inc.India
Greencore Pharma, Inc.
DRP-11927
May 20, 2027
MornemMeropenem
500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1’s)
Rx
Uni Medicolabs, Inc.India
Greencore Pharma, Inc.
DRP-11926
May 20, 2027
MPEN 1000Meropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Ampoule Sterile Water for Injection x 10 mL (diluent) (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
GX International, Inc.Importer: Ambica International Corporation
DRP-10484
Sep 29, 2029
MyrronemMeropenem (as trihydrate)
1 g Powder for Injection (IV)30-mL capacity Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum-flip off cap (Box of 1's and 10's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-12183
Jun 27, 2027
MyrronemMeropenem (as trihydrate)
500 mg Powder for Injection (I.V.)10-mL capacity Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum-flip off cap (Box of 1's and 10's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-12182
Feb 4, 2031
NatronemMeropenem (as trihydrate)
1 g Powder for Injection (IV)USP Type I glass vial (Box of 1’s); USP Type I glass vial (Box of 10’s)
Rx
Samjin Pharmaceutical Co., Ltd.Republic of Korea
Patriot Pharmaceuticals Corporation
DR-XY43762
Oct 29, 2029
NatronemMeropenem (as trihydrate)
500 mg Powder for Injection (IV)USP Type I glass vial Box of 1’s; USP Type I glass vial Box of 10’s
Rx
SAMJIN PHARMACEUTICAL CO., LTD.Republic of Korea
Patriot Pharmaceuticals Corporation
DR-XY43763
Oct 29, 2029
Nemosea-500Meropenem (as trihydrate)
500 mg Powder for Solution for Intravenous (I.V.) InjectionUSP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and sealed with Aluminum Flip Off Seal x 20 mL (Box of l's)
Rx
Brooks Laboratories LimitedIndia
Seapharma International, Inc.
DRP-12722
Sep 28, 2027
NoneMeropenem
1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Uni Medicolabs, Inc.India
HLM Pharmaceutical Inc.Importer: Greencore Pharma, Inc.
DRP-11927-05
May 20, 2027
NoneMeropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6369-03
Oct 2, 2030
NoneMeropenem (as trihydrate)
1 g Powder for IV InjectionType I clear glass vial (Box of 10's)
Rx
Savior Lifetec Corporation Tainan Branch (Injection Plant)China
Ritemed Phils., Inc.
DR-XY46321
Apr 26, 2028
NoneMeropenem (as trihydrate)
1 g Powder for Solution for Injection (I.V.)USP Type II Glass Vial (Box of 1 vial)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-15004-01
Mar 7, 2029
NoneMeropenem (as trihydrate)
1 g Powder for Solution for Injection (IV)Type III glass vial x 20 mL enclosed with bromobutyl rubber stopper and aluminum grey flip-off seal (Box of 10's)
Rx
ACS Dobfar S.p.A.Italy
OneSource Pharma Solutions, Inc.
DRP-8598
Dec 20, 2029
NoneMeropenem (as Trihydrate)
500 mg Powder for I.V. InjectionType I clear glass vial (Box of 10's)
Rx
Savior Lifetec Corporation Tainan Branch (Injection Plant)China
Ritemed Phils., Inc.
DR-XY46320
Apr 26, 2028
NoneMeropenem (as trihydrate)
500 mg Powder for Solution for I.V. InjectionColorless Glass Vial Type III Sealed with Grey Rubber Stopper and Aluminum Cap with Plastic Flip-Off Seal 20 mL-capacity (Box of 1 vial)
Rx
Anfarm Hellas S.A.Greece
Saifen Drugs Philippines, Inc.Trader: Pharmaten S.A.
DRP-15232
Jan 19, 2029
NoneMeropenem (as trihydrate)
500 mg Powder for Solution for Injection (IV)Type III Glass Vial x 20 mL Enclosed with Bromobutyl Rubber Stopper and Aluminum Purple Flip-Off Seal (Box of 10's)
Rx
ACS Dobfar S.p.A.Italy
OneSource Pharma Solutions, Inc.
DRP-8599
Dec 20, 2029
One-Mero 1000Meropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL-capacity Type I Clear Glass Vial with Bromobutyl rubber stopper and Aluminum Flip-off Seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
One Dexcel Pharma Inc.
DRP-12537
Aug 31, 2027
OppironemMeropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's and 10's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Orientphil Pharma Inc.Importer: Ambica International Corporation
DRP-6369-05
Oct 2, 2030
Orem-PMeropenem (as trihydrate)
1 g Powder for Injection (IV Infusion)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminium Cap with Red Flip-Off Seal (Box of 10's)
Rx
JW Pharmaceutical CorporationRepublic of Korea
Medirich Pharma Distribution Corp.Importer: H & B Pharma International Inc.
DRP-16414-01
Jun 23, 2029
PharmanemMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
228 Pharma TradingImporter: Sanimed Pharmaceuticals Inc.
DRP-7074-12
Mar 6, 2027
Plemonem 1000Meropenem (as Trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 5's)
Rx
Daffodills Pharmaceuticals Ltd.India
Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-05
Mar 6, 2027
Plemonem 1000Meropenem (as Trihydrate)
1 g Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Purple Flip-off Seal x 30 mL (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-6527-9
May 18, 2027
Plemonem 500Meropenem (as Trihydrate)
500 mg Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Red Flip-off Seal x 20 mL (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals, Inc.
DRP-6528-08
Feb 12, 2031
PospenemMeropenem (as trihydrate)
1 g Powder for Injection (IV Infusion)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminium Cap with Red Flip-Off Seal (Box of 10's)
Rx
JW Pharmaceutical CorporationRepublic of Korea
H & B Pharma International Inc.
DRP-16414
Jun 23, 2029
PospenemMeropenem (as trihydrate)
500 mg Powder for Injection (IV Infusion)USP Type I Clear Colorless Glass Vial with chlorobutyl rubber stopper and aluminum cap with blue flip-off seal (Box of 10's)
Rx
JW Pharmaceutical CorporationRepublic of Korea
Medlink Marketing Inc.
DR-XY44656
Jun 17, 2031
ProphemMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
GPC Geo Pharma CorporationImporter: Sanimed Pharmaceuticals Inc.
DRP-7074-03
Mar 6, 2027
Q-PenemMeropenem (as trihydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1’s)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-9055-03
Oct 30, 2031
RetapenemMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Reta DrugImporter: Sanimed Pharmaceuticals Inc.
DRP-7074-09
Mar 6, 2027
Rmero-1000Meropenem (as trihydrate)
1 g Powder for Injection (I.V.)20 mL Type I clear glass vial + 10 mL ampoule Sterile Water for Injection (as diluent) [Box of 1's]
Rx
Brawn Laboratories LimitedIndia
Rifemedica CorporationImporter: SBRG Exim Philippines Inc.
DRP-14001-03
Jun 1, 2028
RomapenMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd.
DR-XY44914
Jan 25, 2031
RomepenMeropenem (as trihydrate)
1g Powder for Injection (IV)20 mL-capacity USP Type III clear and colorless glass vial with white flip-off seal Box of 10's and 1's
Rx
Cosmas Research Lab Ltd.India
Endure Medical, Inc.
DR-XY46037
Sep 27, 2027
RomepenMeropenem (as trihydrate)
500mg Powder for Injection (I.V.)10mL USP Type III colorless glass vial (Box of 10's and 1's)
Rx
Cosmas Research Lab Ltd.India
Endure Medical, Inc.
DR-XY45926
Jun 6, 2027
RopenMeropenem (as trihydrate)
1 g Powder for Injection (IV)Type I Colorless Glass Vial (Box of 1's)
Rx
L.B.S. Laboratory Limited PartnershipThailand
Phil Pharmawealth, Inc.
DR-XY37065
Nov 24, 2027
RopenefixMeropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
D&G PharmaImporter: Ambica International Corporation
DRP-6369-01
Oct 2, 2030
Shepenem-1Meropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure with pink flip-off seal Box of 1's
Rx
Daffodills Pharmaceuticals Ltd.India
Dynasty PharmaceuticalsImporter: Sanimed Pharmaceuticals Inc.
DRP-7074-01
Mar 6, 2027
Siti - Penem 1000Meropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL-capacity Type I clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Sahar International Trading Inc.Importer: One Dexcel Pharma Inc.
DRP-12537-01
Aug 31, 2027
Siti-Penem 500Meropenem (as trihydrate)
500 mg Powder for Injection (IV)Type I Clear Glass Vial x 20 mL with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Sahar International Trading Inc.Importer: One Dexcel Pharma Inc.
DRP-12540-01
Aug 30, 2027
SitipenamMeropenem (as trihydrate)
1 g Powder for Injection (I.V.)USP Type I Clear Glass Vial (Box of 1's)
Rx
Intracin PharmaceuticalsIndia
Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc.
DR-XY44090
Feb 20, 2037
Surinem-1000Meropenem (as trihydrate)
1g Powder for injection (IV)20 mL-Capacity USP Type I Glass vial with grey bromobutyl rubber stopper and sky blue colored aluminum flip-off seal (Box of 1's)
Rx
Brooks Laboratories Limited.India
Pharma-Surrey International, Inc.Trader: Sherrington Pharmaceuticals (s) Pte., Ltd
DRP-13235
Jan 6, 2028
Surinem-500Meropenem (as trihydrate)
500 mg Powder for injection (IV)20 mL-capacity USP Type I glass vial with grey bromobutyl rubber stopper and red colored aluminum flip-off seal (Box of 1's)
Rx
Brooks Laboratories LimitedIndia
Pharma-Surrey International, Inc.Trader: Sherrington Pharmaceuticals (s) Pte, Ltd.
DRP-13216
Jan 6, 2028
SymeroMeropenem (as trihydrate)
1 g Powder for Injection (IV)20 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Closure with Pink Flip-Off Seal (Box of 1's)
Rx
Daffodills Pharmaceuticals Ltd.India
Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7074-08
Mar 6, 2027
SyropenMeropenem (as Trihydrate)
500 mg Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Red Flip-off Seal x 20 mL (Box of 1's)
Rx
Brooks Steriscience LimitedIndia
Sanimed Pharmaceuticals, Inc.
DRP-6528
Feb 12, 2031
TripemMeropenem
1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's)
Rx
Uni Medicolabs Inc.India
Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc.
DRP-11927-01
May 20, 2027
TripemMeropenem
500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's)
Rx
Uni MedicolabsIndia
Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc.
DRP-11926-01
May 20, 2027
Unomero 1000Meropenem
1g Powder for Injection (I.V.)20 mL USP Type I glass vial with grey bromobutyl rubber stopper and grey aluminum flip-off seal + 10 mL LDPE ampoule of Sterile Water for Injection X 2 (diluent) (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
S.M.H.P. Marketing & ConsultancyTrader: Unosource Pharma Ltd.
DRP-11999
May 27, 2027
VopenemMeropenem (as trihydrate)
1g Powder for Solution for Injection (IV)Type I clear glass vial x 20 mL with rubber stopper and aluminum purple flip-off seal (Box of 1's)
Rx
Venus Remedies LimitedIndia
Divjot Enterprise Corp.
DR-XY49220
Sep 24, 2029
WelopenemMeropenem (as trihydrate)
1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial Box of 1’s
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
Connectwell Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-9055-02
Oct 26, 2031
Winmero-1000Meropenem (as Trihydrate)
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's and 10's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambica International Corporation
DRP-6369
Oct 2, 2030
XanemMeropenem (as Trihydrate)
1g Powder for Injection (IM/IV)20 mL capacity moulded soda lime glass vial (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-9055
Oct 31, 2031
ZeronemMeropenem (as trihydrate)
1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20 mL (5 Vials per Plastic Tray) (Box of 10's)
Rx
BCWorld Healtchare Co., Ltd.Korea
Central West Medicale Inc.Importer: JLT Pharma Inc.
DRP-6955-05
Jan 4, 2027
Zeronem 500Meropenem (as trihydrate)
500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's)
Rx
BCWorld Healthcare Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: JLT Pharma Inc.
DRP-7859-04
May 31, 2028
(no brand name)Meropenem (as trihydrate)
500mgl Powder for I.V InjectionColorless Glass Vial Type III Sealed with Grey Rubber Stopper and Aluminum Cap with Plastic Flip-Off Seal 20 mL-capacity (Box of 1 vial)
Rx
Anfarm Hellas S.AGreece
Saifen Drugs Philippines, Inc.Trader: Pharmaten S.A
DR-XY48980
Jan 19, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Single dose clear glass vials of meropenem for injection containing 500 mg or 1 gram (as the trihydrate blended with anhydrous sodium carbonate for re-constitution) of sterile meropenem powder. 500 mg Meropenem for Injection Vial (3) 1 gram Meropenem for Injection Vial (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams. (5.1)
  • Severe cutaneous adverse reactions have been reported in patients receiving meropenem. (5.2)
  • Seizures and other adverse CNS experiences have been reported during treatment. (5.3)
  • Co-administration of meropenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. (5.4, 7.2)
  • Clostridium difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs. (5.5)
  • In patients with renal dysfunction, thrombocytopenia has been observed. (5.8)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam.

Before initiating therapy with meropenem, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. If an allergic reaction to meropenem occurs, discontinue the drug immediately.

5.2 Severe Cutaneous Adverse Reactions

5.2 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem [see Adverse Reactions (6.2)]. If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.

5.3 Seizure Potential

5.3 Seizure Potential Seizures and other adverse CNS experiences have been reported during treatment with meropenem. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function [see Adverse Reactions (6.1), Drug Interactions (7.2)].

During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with the overall seizure rate being 0.7% (based on 20 patients with this adverse event). All meropenem-treated patients with seizures had pre-existing contributing factors. Among these are included prior history of seizures or CNS abnormality and concomitant medications with seizure potential.

Dosage adjustment is recommended in patients with advanced age and/or adult patients with creatinine clearance of 50 mL/min or less [see Dosage and Administration (2.2)]. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity. Continue anti-convulsant therapy in patients with known seizure disorders.

If focal tremors, myoclonus, or seizures occur, evaluate neurologically, placed on anti-convulsant therapy if not already instituted, and re-examine the dosage of meropenem to determine whether it should be decreased or discontinued.

5.4 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid

5.4 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.

The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. Consider administration of antibacterial drugs other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.

If administration of meropenem is necessary, consider supplemental anti-convulsant therapy [see Drug Interactions (7.2)].

5.5 Clostridium difficile-associated Diarrhea

5.5 Clostridium difficile-associated Diarrhea Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including meropenem, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.6 Development of Drug-Resistant Bacteria

5.6 Development of Drug-Resistant Bacteria Prescribing meropenem in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

5.7 Overgrowth of Nonsusceptible Organisms

5.7 Overgrowth of Nonsusceptible Organisms As with other broad-spectrum antibacterial drugs, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient is essential. If superinfection does occur during therapy, appropriate measures should be taken.

5.8 Thrombocytopenia

5.8 Thrombocytopenia In patients with renal impairment, thrombocytopenia has been observed but no clinical bleeding reported [see Dosage and Administration (2.2), Adverse Reactions (6.1), Use in Specific Populations (8.5), (8.6), Clinical Pharmacology (12.3)].

5.9 Potential for Neuromotor Impairment

5.9 Potential for Neuromotor Impairment Alert patients receiving meropenem on an outpatient basis regarding adverse events such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that meropenem is well tolerated, advise patients not to operate machinery or motorized vehicles [see Adverse Reactions (6.1)].

Drug interactions

Drug or classSeverityEffectWhat to do
Valproic acid or divalproexAvoidValproate levels can fall below the therapeutic range; breakthrough seizures.Generally not recommended; prefer a non-carbapenem; if needed, consider supplemental anticonvulsant.
ProbenecidAvoidCompetes for tubular secretion; higher meropenem levels.Coadministration not recommended.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • Co-administration of meropenem with probenecid inhibits renal excretion of meropenem and is therefore not recommended. (7.1)
  • The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. (5.4, 7.2)
7.1 Probenecid

7.1 Probenecid Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended.

7.2 Valproic Acid

7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of meropenem is necessary, then supplemental anti-convulsant therapy should be considered [see Warnings and Precautions (5.4)].

Adverse reactions

Common

  • Headache, nausea, constipation, diarrhea, anemia, vomiting, rash (≥2%)

Serious

  • Serious, occasionally fatal hypersensitivity
  • Severe cutaneous adverse reactions
  • Rhabdomyolysis
  • Seizures and other CNS effects
  • Clostridioides difficile-associated diarrhea
  • Thrombocytopenia (in kidney impairment)
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following are discussed in greater detail in other sections of labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] Seizure Potential [see Warnings and Precautions (5.3)] Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid [see Warnings and Precautions (5.4)] Clostridium difficile - associated Diarrhea [see Warnings and Precautions (5.5)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.6)] Overgrowth of Nonsusceptible Organisms [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Potential for Neuromotor Impairment [see Warnings and Precautions (5.9)] Most common adverse reactions (2% or less) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Savior Lifetec Corporation at 886-6-505-1200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Adverse Reactions from Clinical Trials

6.1 Adverse Reactions from Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients: During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with meropenem (500 mg or 1 gram every 8 hours).

Deaths in 5 patients were assessed as possibly related to meropenem; 36 (1.2%) patients had meropenem discontinued because of adverse events. Many patients in these trials were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies. In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with meropenem.

The following adverse reaction frequencies were derived from the clinical trials in the 2904 patients treated with meropenem. Local Adverse Reactions Local adverse events that were reported with meropenem were as follows: Inflammation at the injection site 2.4% Injection site reaction 0.9% Phlebitis/thrombophlebitis 0.8% Pain at the injection site 0.4% Edema at the injection site 0.2% Systemic Adverse Reactions Systemic adverse events that were reported with meropenem occurring in greater than 1.0% of the patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%).

Additional systemic adverse events that were reported with meropenem and occurring in less than or equal to 1.0% but greater than 0.1% of the patients are listed below within each body system in order of decreasing frequency: Bleeding events were seen as follows: gastrointestinal hemorrhage (0.5%), melena (0.3%), epistaxis (0.2%), hemoperitoneum (0.2%). Body as a Whole: pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, pelvic pain Cardiovascular: heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension, syncope Digestive System: oral moniliasis, anorexia, cholestatic jaundice/jaundice, flatulence, ileus, hepatic failure, dyspepsia, intestinal obstruction Hemic/Lymphatic: anemia, hypochromic anemia, hypervolemia Metabolic/Nutritional: peripheral edema, hypoxia Nervous System: insomnia, agitation, delirium, confusion, dizziness, seizure, nervousness, paresthesia, hallucinations, somnolence, anxiety, depression, asthenia [see Warnings and Precautions (5.3), (5.9)] Respiratory: respiratory disorder, dyspnea, pleural effusion, asthma, cough increased, lung edema Skin and Appendages: urticaria, sweating, skin ulcer Urogenital System: dysuria, kidney failure, vaginal moniliasis, urinary incontinence Adverse Laboratory Changes Adverse laboratory changes that were reported and occurring in greater than 0.2% of the patients were as follows: Hepatic: increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, lactate dehydrogenase (LDH), and bilirubin Hematologic: increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cell (WBC), shortened prothrombin time and shortened partial thromboplastin time, leukocytosis, hypokalemia Renal: increased creatinine and increased blood urea nitrogen (BUN) Urinalysis: presence of red blood cells Complicated Skin and Skin Structure Infections In a study of complicated skin and skin structure infections, the adverse reactions were similar to those listed above.

The most common adverse events occurring in greater than 5% of the patients were: headache (7.8%), nausea (7.8%), constipation (7.0%), diarrhea (7.0%), anemia (5.5%), and pain (5.1%). Adverse events with an incidence of greater than 1%, and not listed above, include: pharyngitis, accidental injury, gastrointestinal disorder, hypoglycemia, peripheral vascular disorder, and pneumonia.

Patients with Renal Impairment: For patients with varying degrees of renal impairment, the incidence of heart failure, kidney failure, seizure and shock reported with meropenem, increased in patients with moderately severe renal impairment (creatinine clearance 10 to 26 mL/min) [see Dosage and Administration (2.2), Warnings and Precautions (5.9), Use in Specific Populations (8.5), (8.6), Clinical Pharmacology (12.3)]. Pediatric Patients: Systemic and Local Adverse Reactions Pediatric Patients with Serious Bacterial Infections (excluding Bacterial Meningitis): Meropenem was studied in 515 pediatric patients (3 months to less than 13 years of age) with serious bacterial infections (excluding meningitis, see next section) at dosages of 10 mg/kg to 20 mg/kg every 8 hours.

The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem and their rates of occurrence as follows: Diarrhea 3.5% Rash 1.6% Nausea and Vomiting 0.8% Pediatric Patients with Bacterial Meningitis: Meropenem was studied in 321 pediatric patients (3 months to less than 17 years of age) with meningitis at a dosage of 40 mg/kg every 8 hours. The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse reactions reported as possibly, probably, or definitely related to Meropenem and their rates of occurrence as follows: Diarrhea 4.7% Rash (mostly diaper area moniliasis) 3.1% Oral Moniliasis 1.9% Glossitis 1.0% In the meningitis studies, the rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents (either cefotaxime or ceftriaxone).

In the meropenem treated group, 12/15 patients with seizures had late onset seizures (defined as occurring on day 3 or later) versus 7/20 in the comparator arm. The meropenem group had a statistically higher number of patients with transient elevation of liver enzymes. Pediatric Patients (Neonates and Infants less than 3 months of Age): Meropenem was studied in 200 neonates and infants less than 3 months of age.

The study was open-label, uncontrolled, 98% of the infants received concomitant medications, and the majority of adverse events were reported in neonates less than 32 weeks gestational age and critically ill at baseline, making it difficult to assess the relationship of the adverse events to meropenem. The adverse reactions seen in these patients that were reported and their rates of occurrence are as follows: Convulsion 5.0% Hyperbilirubinemia (conjugated) 4.5% Vomiting 2.5% Adverse Laboratory Changes in Pediatric Patients: Laboratory changes seen in the pediatric studies, including the meningitis studies, were similar to those reported in the adult studies.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of meropenem. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Worldwide post-marketing adverse reactions not otherwise listed in the Adverse Reactions from Clinical Trials section of this prescribing information and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity. Blood and Lymphatic System Disorders: agranulocytosis, neutropenia, and leukopenia; a positive direct or indirect Coombs test, and hemolytic anemia.

Immune System Disorders: angioedema. Skin and Subcutaneous Disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and acute generalized exanthematous pustulosis.

Adverse reaction frequency tables (US label) US FDA label
Inflammation at the injection site 2.4%
Injection site reaction 0.9%
Phlebitis/thrombophlebitis 0.8%
Pain at the injection site 0.4%
Edema at the injection site 0.2%
Diarrhea 3.5%
Rash 1.6%
Nausea and Vomiting 0.8%
Diarrhea 4.7%
Rash (mostly diaper area moniliasis) 3.1%
Oral Moniliasis 1.9%
Glossitis 1.0%
Convulsion 5.0%
Hyperbilirubinemia (conjugated) 4.5%
Vomiting 2.5%

Monitoring parameters

  • Seizure risk higher in kidney impairment and central nervous system disease; do not combine with valproate (label class warnings). Kidney
  • Creatinine clearance for dosing
  • Seizure activity, especially with CNS disorders or kidney impairment
  • Valproate levels if coadministered
  • Platelet count in kidney impairment
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women. No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively.

In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Meropenem administered to pregnant rats during organogenesis (Gestation Day 6 to Gestation Day 17) in intravenous doses of 240, 500, and 750 mg/kg/day was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity.

The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/day (equivalent to approximately 2.4 times the MRHD of 1 gram every 8 hours based on body surface area comparison). Meropenem administered intravenously to pregnant Cynomolgus monkeys during organogenesis from Day 20 to 50 after mating at doses of 120, 240, and 360 mg/kg/day did not produce maternal or fetal toxicity at the NOAEL dose of 360 mg/kg/day (approximately 2.3 times the MRHD based on body surface area comparison).

In a peri-postnatal study in rats described in the published literature 2, intravenous meropenem was administered to dams from Gestation Day 17 until Lactation Day 21 at doses of 240, 500, and 1000 mg/kg/day. There were no adverse effects in the dams and no adverse effects in the first generation offspring (including developmental, behavioral, and functional assessments and reproductive parameters) except that female offspring exhibited lowered body weights which continued during gestation and nursing of the second generation offspring.

Second generation offspring showed no meropenem-related effects. The NOAEL value was considered to be 1000 mg/kg/day (approximately 3.2 times the MRHD based on body surface area comparisons).

Mechanism of action

12.1 Mechanism of Action Meropenem is an antibacterial drug [see Microbiology (12.4)].

Mechanism of Action The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to bind penicillin-binding-protein (PBP) targets. Meropenem binds to PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus.

Bactericidal concentrations (defined as a 3 log 10 reduction in cell counts within 12 hours to 24 hours) are typically 1 to 2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed. Meropenem does not have in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE).

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best correlate with efficacy in animal and in vitro models of infection.

Pharmacokinetics

Key PK parameters

Time to peakEnd of 30-minute infusion: about 23 mcg/mL (500 mg) and 49 mcg/mL (1 g); 5-minute bolus: about 45 mcg/mL (500 mg) and 112 mcg/mL (1 g)
Half-lifeAbout 1 hour
Half-life in kidney failure (ESKD) kidneyAbout 6.8 hours in ESKD (vs 0.9 hours healthy; Christensson 1992); 7.0 hours off dialysis, 2.9 hours during hemodialysis (Chimata 1993)
Protein bindingAbout 2%
Metabolism (CYP, transporters)One microbiologically inactive metabolite (about 28% of dose)
Active metabolitesNone
Renal excretion kidneyAbout 70% (50% to 75%) unchanged in urine within 12 hours
Dialyzability kidneyYes: readily dialyzable and effectively removed by hemodialysis (label); dialysis clearance about 79 mL/min/1.73 m2 (Christensson 1992).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Excretion Meropenem is primarily excreted unchanged by the kidneys.

Approximately 70% (50% - 75%) of the dose is excreted unchanged within 12 hours.

The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.

Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose.

The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Plasma Concentrations At the end of a 30-minute intravenous infusion of a single dose of meropenem in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 mcg/mL (range 14 to 26) for the 500 mg dose and 49 mcg/mL (range 39 to 58) for the 1 gram dose. A 5-minute intravenous bolus injection of meropenem in healthy volunteers results in mean peak plasma concentrations of approximately 45 mcg/mL (range 18 to 65) for the 500 mg dose and 112 mcg/mL (range 83 to 140) for the 1 gram dose.

Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration. No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 gram administered every 6 hours in healthy volunteers with normal renal function.

Distribution The plasma protein binding of meropenem is approximately 2%. After a single intravenous dose of meropenem, the highest mean concentrations of meropenem were found in tissues and fluids at 1 hour (0.5 hours to 1.5 hours) after the start of infusion, except where indicated in the tissues and fluids listed in Table 5 below.

Table 5: Meropenem Concentrations in Selected Tissues (Highest Concentrations Reported) Tissue Intravenous. Dose (gram) Number of Samples Mean [mcg/mL or mcg/(gram)] at 1 hour unless otherwise noted. Range [mcg/mL or mcg/(gram)] Endometrium 0.5 7 4.2 1.7-10.2 Myometrium 0.5 15 3.8 0.4-8.1 Ovary 0.5 8 2.8 0.8-4.8 Cervix 0.5 2 7 5.4-8.5 Fallopian tube 0.5 9 1.7 0.3-3.4 Skin 0.5 22 3.3 0.5-12.6 Interstitial fluid obtained from blister fluid. 0.5 9 5.5 3.2-8.6 Skin 1 10 5.3 1.3-16.7 Interstitial fluid 1 5 26.3 20.9-37.4 Colon 1 2 2.6 2.5-2.7 Bile 1 7 14.6 (3 hours) 4-25.7 Gall bladder 1 1 — 3.9 Peritoneal fluid 1 9 30.2 7.4-54.6 Lung 1 2 4.8 (2 hours) 1.4-8.2 Bronchial mucosa 1 7 4.5 1.3-11.1 Muscle 1 2 6.1 (2 hours) 5.3-6.9 Fascia 1 9 8.8 1.5-20 Heart valves 1 7 9.7 6.4-12.1 Myocardium 1 10 15.5 5.2-25.5 CSF (inflamed) 20 mg/kg in pediatric patients of age 5 months to 8 years. 40 mg/kg in pediatric patients of age 1 months to 15 years. 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2-2.8 0.9-6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1-0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.

Metabolism There is one metabolite of meropenem that is microbiologically inactive. Excretion Meropenem is primarily excreted unchanged by the kidneys. Approximately 70% (50% - 75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Fecal elimination represents only approximately 2% of the dose.

The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion. Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose. Specific Populations Patients with Renal Impairment Pharmacokinetic studies with meropenem in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance.

Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less) [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Meropenem is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [see Overdosage (10)]. Patients with Hepatic Impairment A pharmacokinetic study with meropenem in patients with hepatic impairment has shown no effects of liver disease on the pharmacokinetics of meropenem.

Geriatric Patients A pharmacokinetic study with meropenem in elderly patients with renal impairment showed a reduction in plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance. Pediatric Patients The pharmacokinetics of meropenem, in pediatric patients 2 years of age or older, are similar to those in adults.

The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years. The pharmacokinetics of meropenem in patients less than 3 months of age receiving combination antibacterial drug therapy are given below. Table 6: Meropenem Pharmacokinetic Parameters in Patients Less Than 3 Months of Age Values are derived from a population pharmacokinetic analysis of sparse data GA less than 32 weeks PNA less than 2 weeks (20mg/kg every 12 hours) GA less than 32 weeks PNA 2 weeks or older (20mg/kg every 8 hours) GA 32 weeks or older PNA less than 2 weeks (20mg/kg every 8 hours) GA 32 weeks or older PNA 2 weeks or older (30mg/kg every 8 hours) Overall CL (L/h/kg) 0.089 0.122 0.135 0.202 0.119 V (L/kg) 0.489 0.467 0.463 0.451 0.468 AUC 0-24 (mcg-h/mL) 448 491 445 444 467 C max (mcg/mL) 44.3 46.5 44.9 61 46.9 C min (mcg/mL) 5.36 6.65 4.84 2.1 5.65 T 1/2 (h) 3.82 2.68 2.33 1.58 2.68 Drug Interactions Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.

Following administration of probenecid with meropenem, the mean systemic exposure increased 56% and the mean elimination half-life increased 38% [see Drug Interactions (7.1)].

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Meropenem 1 g Vial₱143.22–₱840.00Reference ₱156.45per vialDPRI procurement range
Meropenem 500 mg Vial₱97.33–₱540.00Reference ₱104.39per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Meropenem (as trihydrate)
PNF listingInj.: 500 mg and 1 g powder, vial (IV)Restrictions: Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. MEROPENEM · Civica, Inc [US FDA-approved label, version 7, November 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0075b72-c3cc-f844-e053-2a95a90a417f
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Civica, Inc. (2026). Meropenem for injection, USP (meropenem; single-dose vials, 500 mg and 1 g) [Prescribing information; US FDA-approved label, ANDA206086, set ID b0075b72-c3cc-f844-e053-2a95a90a417f, version effective November 2, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0075b72-c3cc-f844-e053-2a95a90a417f
  6. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  7. Shaw, A. R., & Mueller, B. A. (2017). Antibiotic dosing in continuous renal replacement therapy. Advances in Chronic Kidney Disease, 24(4), 219–227. https://doi.org/10.1053/j.ackd.2017.05.004
  8. Roberts, J. A., Abdul-Aziz, M. H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016). Continuous versus intermittent β-lactam infusion in severe sepsis: A meta-analysis of individual patient data from randomized trials. American Journal of Respiratory and Critical Care Medicine, 194(6), 681–691. https://doi.org/10.1164/rccm.201601-0024OC
  9. Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., Liu, X., McGuinness, S., Mysore, J., Paterson, D. L., Peake, S., Rhodes, A., Roberts, J. A., Roger, C., Shirwadkar, C., ... Lipman, J. (2024). Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial. JAMA, 332(8), 629–637. https://doi.org/10.1001/jama.2024.9779
  10. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
  11. Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
  12. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
  13. Christensson, B. A., Nilsson-Ehle, I., Hutchison, M., Haworth, S. J., Oqvist, B., & Norrby, S. R. (1992). Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrobial Agents and Chemotherapy, 36(7), 1532–1537. https://doi.org/10.1128/AAC.36.7.1532
  14. Chimata, M., Nagase, M., Suzuki, Y., Shimomura, M., & Kakuta, S. (1993). Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrobial Agents and Chemotherapy, 37(2), 229–233. https://doi.org/10.1128/AAC.37.2.229

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .